Specifically vemurafenib or dabrafenib either as single agents or in combination with the MEK‐inhibitors cobimetinib or trametinib, produced objective response rates between 50% and 70%, and improved median progression‐free and overall survival in patients with BRAF‐mutant advanced or metastatic melanoma, leading to their FDA‐approvals 18, 19, 20, 21, 22. Here, MAP2K7 is linked to metastatic melanoma.